The ophthalmologist from John A. Moran Eye Center discussed the close association between disease progression and uncovered risk alleles.
Steffen Schmitz-Valckenberg, MD
Advertisement
Articles by Steffen Schmitz-Valckenberg, MD
Advertisement
Latest Updated Articles
Uptake of Nononcology Gene Therapy Remains Slow in HematologyPublished: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLDPublished: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 DataPublished: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell TherapyPublished: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMDPublished: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of VisionPublished: May 18th 2023 | Updated:
Advertisement
Advertisement
Trending on CGTlive®
1
Patients With DMD Treated With Avidity Biosciences’ Antibody Oligonucleotide Conjugate Del-Zota Show Functional Improvements
2
In Response to FDA’s Release of Full CRL for Deramiocel, Capricor Publishes Full Response to the Agency
3
Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025
4
